Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26999922 | 0.95 | TSHR (0.44) | SMN1; SMN2TSHREPHX2CHRM3CYP1A2 | |
| SCHEMBL13673248 | 0.91 | CYP1A2 (0.47) | SMN1; SMN2TSHREPHX2CYP1A2 | |
| SCHEMBL26729103 | 0.83 | CHRM3 (0.42) | SMN1; SMN2CHRM3CYP1A2CHRNB2CHRNA5 | |
| SCHEMBL14569846 | 0.82 | CYP1A2 (0.43) | SMN1; SMN2TSHRCHRM3CYP1A2CHRNB2 | |
| SCHEMBL26211648 | 0.82 | CYP1A2 (0.43) | SMN1; SMN2TSHRCHRM3CYP1A2CHRNB2 | |
| SCHEMBL12847853 | 0.82 | ALDH1A1 (0.43) | SMN1; SMN2EPHX2CHRM3CYP1A2CHRNB2 | |
| SCHEMBL29039246 | 0.82 | TSHR (0.40) | SMN1; SMN2TSHREPHX2 | |
| SCHEMBL31578891 | 0.82 | SLC2A1 (0.39) | SMN1; SMN2EPHX2ALDH1A1 | |
| SCHEMBL12847854 | 0.81 | SMN1; SMN2 (0.38) | SMN1; SMN2CHRM3CYP1A2CHRNB2CHRNA5 | |
| SCHEMBL19376421 | 0.79 | CYP1A2 (0.57) | CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | SMN1; SMN2 2633/4885TSHR 2355/4885EPHX2 3576/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | SMN1; SMN2 2633/4885TSHR 2355/4885EPHX2 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.